Now after 2021 comes to an end we can summarize that HopeMedicine failed terribly in their plans to do clinical trials for HMI-115 against Androgenetic Alopecia. They claimed last year that the pandemic wouldnt have dramatic effects on their timeline and that they are on track to start clinical trials in europe, australia an USA against hair loss.
They received a big investment in May 2021 (60 Mio. $). They changed CEO Rui-Ping to Henri Nico Doods.
Unfortunately we are now aware that HopeMedicine prefers the Endometriosis treatment over the alopecia treatment.
They weren't able to start their alopecia trial. I know some members here will say that HopeMedicine has no influence on the timelines of the FDA or the COVID-situation BUT I am convinced that HopeMedicine should be experienced enough to think about the risks of their timeline in respect to FDA-approval and then shouldnt make claims that they would start the trials in summer 2021...
It is questionable whether Hopemedicine starts in 2022 with the alopecia trial or is now focused in finishing the endometriosis trial which will take until end of 2023. Maybe they want to check up this risk profile before starting the alopecia trial
After all this encouraging discussion in this thread regarding HMI-115 and its very exciting results (monkey pictures) it let me down to an huge dissapointment and a very bad year for hairloss industry 2021...